ANTIPODES PARTNERS Ltd Acquires Shares of 1,568 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

ANTIPODES PARTNERS Ltd acquired a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 1,568 shares of the biopharmaceutical company’s stock, valued at approximately $57,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RARE. Vanguard Group Inc. boosted its holdings in shares of Ultragenyx Pharmaceutical by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 10,034,862 shares of the biopharmaceutical company’s stock valued at $422,167,000 after purchasing an additional 89,389 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company’s stock valued at $71,509,000 after purchasing an additional 25,487 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 5.3% during the fourth quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company’s stock worth $68,487,000 after buying an additional 81,667 shares in the last quarter. Vestal Point Capital LP increased its holdings in shares of Ultragenyx Pharmaceutical by 100.0% during the fourth quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $63,105,000 after buying an additional 750,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 23.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,439,740 shares of the biopharmaceutical company’s stock worth $60,570,000 after buying an additional 269,733 shares in the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently issued reports on RARE. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a report on Monday, July 14th. Wells Fargo & Company cut their price target on shares of Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a report on Thursday, July 10th. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, July 14th. JPMorgan Chase & Co. increased their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. Finally, Guggenheim reiterated a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $83.64.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the transaction, the director directly owned 15,344 shares in the company, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.50% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $0.33 during mid-day trading on Thursday, hitting $27.68. The stock had a trading volume of 299,844 shares, compared to its average volume of 1,222,355. The firm has a market cap of $2.62 billion, a P/E ratio of -4.74 and a beta of 0.26. The business has a fifty day moving average price of $35.14 and a 200-day moving average price of $37.94. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.03). The firm had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. Ultragenyx Pharmaceutical had a negative net margin of 93.04% and a negative return on equity of 186.49%. The business’s quarterly revenue was up 28.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.03) earnings per share. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.